Cargando…
Comment on the paper Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab: the likely explanation for this phenomenon based on our observations
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051542/ https://www.ncbi.nlm.nih.gov/pubmed/33864125 http://dx.doi.org/10.1007/s00415-021-10547-0 |
| _version_ | 1783679751141982208 |
|---|---|
| author | Mado, Hubert Adamczyk-Sowa, Monika |
| author_facet | Mado, Hubert Adamczyk-Sowa, Monika |
| author_sort | Mado, Hubert |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8051542 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-80515422021-04-16 Comment on the paper Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab: the likely explanation for this phenomenon based on our observations Mado, Hubert Adamczyk-Sowa, Monika J Neurol Letter to the Editors Springer Berlin Heidelberg 2021-04-16 2021 /pmc/articles/PMC8051542/ /pubmed/33864125 http://dx.doi.org/10.1007/s00415-021-10547-0 Text en © Springer-Verlag GmbH Germany, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Letter to the Editors Mado, Hubert Adamczyk-Sowa, Monika Comment on the paper Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab: the likely explanation for this phenomenon based on our observations |
| title | Comment on the paper Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab: the likely explanation for this phenomenon based on our observations |
| title_full | Comment on the paper Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab: the likely explanation for this phenomenon based on our observations |
| title_fullStr | Comment on the paper Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab: the likely explanation for this phenomenon based on our observations |
| title_full_unstemmed | Comment on the paper Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab: the likely explanation for this phenomenon based on our observations |
| title_short | Comment on the paper Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab: the likely explanation for this phenomenon based on our observations |
| title_sort | comment on the paper negative anti-sars-cov-2 s antibody response following pfizer sars-cov-2 vaccination in a patient on ocrelizumab: the likely explanation for this phenomenon based on our observations |
| topic | Letter to the Editors |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051542/ https://www.ncbi.nlm.nih.gov/pubmed/33864125 http://dx.doi.org/10.1007/s00415-021-10547-0 |
| work_keys_str_mv | AT madohubert commentonthepapernegativeantisarscov2santibodyresponsefollowingpfizersarscov2vaccinationinapatientonocrelizumabthelikelyexplanationforthisphenomenonbasedonourobservations AT adamczyksowamonika commentonthepapernegativeantisarscov2santibodyresponsefollowingpfizersarscov2vaccinationinapatientonocrelizumabthelikelyexplanationforthisphenomenonbasedonourobservations |